Dr. Miguel Saceda Sánchez

Researcher, Universidad Miguel Hernandez-FISABIO

 

]

Unit
Hard to treat cancers

Group
Chemoresistance and Cancer

RESEARCH FIELDS

  • Search for new biomarkers and therapeutic targets of clinical utility for tumours with poor prognosis.
  • Screening and development of new therapeutic strategies for the treatment of glioblastoma.
  • Vehiculisation of antitumour agents in nanoformulations of different natures.
  • Development of new cellular and animal models closer to the patient to study the molecular mechanisms involved in the acquisition of resistance to chemo- and radiotherapy and the screening of new therapeutic strategies

PROFESSIONAL BACKGROUND

  • Previous positions:
    1. Fellowship from FIS (Ministerio de Sanidad). (1982-1985).
    2. Fellowship from Spanish-USA joint Commite (1986-1988).
  • Postdoctoral positions:
    1. N I H, Bethesda, MD, U.S.A. Estrogen receptor and breast cancer. (1986-88).
    2. Georgetown University, Washington DC, U.S.A. Estrogen receptor and breast cancer. (1988-1993).
    3. Georgetown University, Washington D.C., U.S.A. Estrogen receptor and breast cancer. (1997-98).
    4. Universidad Miguel Hernández. Biochemestry and Molecular Biology Deparment (Research contract Generalitat Valenciana). (1998-2000).
    5. Hospital General Universitario de Elche (Research contract Spanish Healt Ministry). (2000-2006).
    6. Fundación para la Investigación Biomédica del Hospital general Universitario de Elche. (2006-Actual).
  • PhD: Universidad Complutense de Madrid (Director. Dra. Isabel Valverde Alonso), 1986.
  • Degree in Biology.